Pfizer Inc. must be hoping to appeal to FDA’s flexibility on orphan drug reviews as the advisory panel tasked with reviewing Vyndaqel (tafamidis meglumine) weighs a dispute between agency and sponsor over the statistical reading of the pivotal trial results, and the agency notes ominously that the bulk of the efficacy seems to come from a single, foreign site.
Most of FDA’s approval decisions for orphan products use unconventional efficacy standards, according to a report released last year by the National Organization for Rare Disorders, which helps make the case for anticipating some regulatory flexibility Also see "
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?